Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Antimicrobial Resistance and Infection Control is a leading open access journal published by BMC, dedicated to the dissemination of research in the critical area of antimicrobial resistance and its impact on infection control practices. Since its inception in 2012, the journal has quickly established itself as a vital resource for researchers, healthcare professionals, and policymakers, featuring a robust array of studies that address the escalating threats posed by antimicrobial resistance across various contexts. With its impressive Q1 rankings across multiple categories—including Infectious Diseases, Microbiology, Pharmacology, and Public Health—the journal’s influence is underscored by its consistent placement in the upper echelons of academic research. Furthermore, it holds commendable ranks in Scopus, with percentiles placing it in the top tier of its respective fields. The journal serves as an essential platform for innovative research and discussions aimed at curbing the threats of antimicrobial resistance, thereby supporting the global health community in striving for effective solutions to safeguard public health.

Southern African Journal of Infectious Diseases is a pivotal platform for the dissemination and advancement of research in the field of infectious diseases, with a particular focus on issues significant to the Southern African region. Published by AOSIS, this Open Access journal has been committed to providing accessible scholarly content since 2016, enabling researchers and practitioners to stay updated with the latest developments in infectious disease epidemiology, prevention, and management. With the ISSN 2312-0053 and E-ISSN 2313-1810, the journal invites submissions that explore diverse topics, including but not limited to clinical studies, public health policies, and innovative treatment methodologies. The Southern African Journal of Infectious Diseases is an essential resource for academics, professionals, and students dedicated to combating infectious diseases and improving health outcomes in the region, fostering a collaborative approach to research and knowledge sharing.

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

The Journal of Global Antimicrobial Resistance, published by Elsevier Scientific Ltd, is a premier open access journal dedicated to addressing the critical issue of antimicrobial resistance on a global scale. Established in 2013 and significantly gaining traction as an open access platform since 2020, this journal serves as an essential resource for researchers, healthcare professionals, and policy makers invested in immunology, microbiology, and associated fields. With an impressive impact factor reflected through its consistent ranking in the Q2 category across multiple disciplines, including Microbiology and Immunology – where it ranks #29 out of 140 in Medical Microbiology – the journal ensures high-quality peer-reviewed articles that push the boundaries of current knowledge and practice. By offering a global perspective on research trends and public health implications, the Journal of Global Antimicrobial Resistance plays a pivotal role in advancing the scientific discourse necessary to combat the rising tide of antimicrobial resistance worldwide.

International Journal of Antimicrobial Agents, published by Elsevier, stands as a premier platform in the fields of Infectious Diseases, Microbiology, and Medical Pharmacology. With an impressive impact factor and ranked in the Q1 category across multiple medical disciplines in 2023, this journal is recognized for its contribution to advancing knowledge and understanding in the efficacy and safety of antimicrobial treatments. Its comprehensive scope from 1991 to 2024 allows for the publishing of original research, reviews, and commentary on pressing issues related to antimicrobial resistance, treatment strategies, and pharmacological innovations. With a strong emphasis on high-quality research as reflected in its Scopus rankings, the journal is an essential resource for researchers, clinicians, and students dedicated to improving patient outcomes in the face of evolving microbiological challenges. Engage with the latest findings and methodologies through this vital academic resource, available in print and online, from the heart of the Netherlands.

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

Antimicrobial Agents and Chemotherapy, published by the American Society for Microbiology, is a leading journal in the fields of Infectious Diseases and Pharmacology. With a rich history dating back to its inception in 1963, this esteemed journal provides a vital platform for the dissemination of innovative research and advances in antimicrobials and therapeutic strategies. Currently holding a remarkable Q1 ranking in multiple categories, including Infectious Diseases and Pharmacology (medical), the journal occupies a prestigious position within its discipline, supported by exceptional rankings in Scopus metrics. As an essential resource for researchers, professionals, and students alike, it aims to foster knowledge exchange and inspire new strategies in combating infectious diseases. While not an open-access journal, it remains influential in shaping clinical applications and public health strategies through its rigorous peer-reviewed publications.

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA is a distinguished academic journal published by AKADEMIAI KIADO ZRT, focusing on significant advancements in the fields of microbiology, immunology, and infectious diseases. Established in 1994, this journal serves as a vital platform for researchers, professionals, and students keen on exploring the complexities of microbial interactions and immune responses. With a current Impact Factor reflecting its rank within the Q3 categories for Immunology, Microbiology, and Infectious Diseases, it retains a critical position in disseminating innovative research. Although not open access, the journal provides extensive insights disseminated through various academic databases, ensuring a broad reach within the scholarly community. Its convergence over three decades indicates a robust commitment to excellence in scientific inquiry and knowledge sharing. As it moves towards the future, ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA continues to uphold its legacy of fostering collaborative research initiatives that contribute to the understanding and treatment of microbial diseases globally.